Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable
and clear relationships exist between exposure and treatment outcomes, fixed dosing is still …

Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes
that are involved in multiple cellular processes. Currently, multiple oral TKIs have been …

Interindividual variability in drug metabolism can significantly affect drug concentrations in
the body and subsequent drug response. Understanding an individual's drug metabolism …

This paper reviews current treatments for renal cell carcinoma/cancer (RCC) with the
multikinase inhibitors (MKIs) sorafenib, sunitinib, lenvatinib and axitinib. Furthermore, it …

Aim Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high
interpatient variability in plasma exposure. A relationship between plasma exposure and …

Abstract Background and Objective Pazopanib is a multi-targeted anticancer tyrosine kinase
inhibitor. This study was conducted to develop a population pharmacokinetic (popPK) model …

Purpose This study aimed to examine the association between the trough plasma
concentration of lenvatinib with the objective response rate (ORR) and adverse events in …

Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure
and the development of acquired resistance is the rule rather than the exception. CDK4/6 …

Hypertension and renal injury are off-target effects of sunitinib, a tyrosine kinase receptor
inhibitor used for the treatment of various tumor types. Importantly, these untoward effects …

The prospect of precision dosing in oncology is attractive for several reasons. Many
anticancer drugs display narrow therapeutic indices, where suboptimal therapy may lead to …